Provided by Tiger Trade Technology Pte. Ltd.

Phio Pharmaceuticals

1.12
-0.0200-1.75%
Volume:183.97K
Turnover:210.46K
Market Cap:12.06M
PE:-0.44
High:1.17
Open:1.16
Low:1.12
Close:1.14
52wk High:9.79
52wk Low:0.9657
Shares:10.76M
Float Shares:10.71M
Volume Ratio:0.39
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5229
EPS(LYR):-9.0798
ROE:-107.58%
ROA:-60.16%
PB:1.23
PE(LYR):-0.12

Loading ...

Company Profile

Company Name:
Phio Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
5
Office Location:
11 Apex Drive,Suite 300A,PMB 2006,Marlborough,Massachusetts,United States
Zip Code:
01752
Fax:
- -
Introduction:
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Directors

Name
Position
Robert J. Bitterman
President, Chief Executive Officer and Chair of the Board
Curtis A. Lockshin
Director
David H. Deming
Director
Jonathan E. Freeman
Director
Patricia A. Bradford
Director

Shareholders

Name
Position
Robert J. Bitterman
President, Chief Executive Officer and Chair of the Board
Lisa Carson
Vice President, Finance and Administration; Principal Financial Officer; Principal Accounting Officer